A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma.
BACKGROUND
Epstein-Barr virus BZLF-1 replication activator (ZEBRA) is involved in the switch from viral latency to a productive cycle. Previous immunofluorescent study has shown that patients with nasopharyngeal carcinoma (NPC) have elevated immunoglobulin-G (IgG) antibody titres against recombinant ZEBRA protein (ZEBRA/IgG).


METHODS
The prognostic role of ZEBRA/IgG was further investigated by enzyme-linked immunosorbent assay (ELISA) in 110 NPC patients under long period of clinical follow-up.


RESULTS
Ninety-seven percent (85 of 88) of the patients with NPC had significantly higher ZEBRA/IgG titres (geometrical mean titre, i.e., GMT = 8397) than normal Chinese individuals (GMT = 233 and P < 0.0001). Based on Kaplan-Meier analysis, the actuarial survival in patients with high ZEBRA/IgG titres (25%) after radiotherapy was significantly lower than that of those with low (76%; P = 0.0008) or intermediate titres (62%; P = 0.0036), although the titres taken before treatment did not bear such a relationship. Subdividing the patients into either individual UICC or Ho's stages, those with late-stage disease (UICC Stage 4 and Ho's Stages 3 and 4) and with high ZEBRA/IgG titres also had poorer prognosis than those with disease of the same stages but who had low titres. Poor prognosis in those with high titres could be associated with a high risk of distant metastasis because consistent titre increase was found in the majority of patients who later developed distant metastasis either in the lung or liver. Only a minimal increase was found in patients with recurrence in the cervical lymph nodes. No consistent increase was observed, however, in patients whose disease was in remission or the majority of those with bone metastasis or local recurrence in the nasopharynx.


CONCLUSIONS
The postradiotherapy ZEBRA/IgG titre could be a potentially useful marker for differentiating NPC patients with poor prognosis from those at high risk for the development of distant metastasis to the lung or liver.
Yip
T T
TT
Radiotherapy and Oncology Division, Queen Elizabeth Hospital, Kowloon, Hong Kong.
Ngan
R K
RK
Lau
W H
WH
Poon
Y F
YF
Joab
I
I
Cochet
C
C
Cheng
A K
AK
D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology*; D004268:DNA-Binding Proteins / Q000032:analysis / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D006566:Herpesviridae Infections / Q000276:immunology*; D004854:Herpesvirus 4, Human / Q000276:immunology* / Q000302:isolation & purification; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy / Q000821:virology*; D011379:Prognosis; D011994:Recombinant Proteins / Q000276:immunology; D012698:Serologic Tests; D015996:Survival Rate; D015534:Trans-Activators / Q000032:analysis / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology* / Q000401:mortality; D014764:Viral Proteins / Q000032:analysis / Q000276:immunology*
C063676:BZLF1 protein, Herpesvirus 4, Human; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D015534:Trans-Activators; D014764:Viral Proteins